menu search

STIM / Why I Am Passing On BrainsWay And Neuronetics

Why I Am Passing On BrainsWay And Neuronetics
I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth. Read More
Posted: Feb 17 2023, 11:46
Author Name: Seeking Alpha
Views: 092111

STIM News  

Neuronetics: Large Losses May Be Repelling Investors

By Seeking Alpha
September 6, 2023

Neuronetics: Large Losses May Be Repelling Investors

Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. more_horizontal

Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith S more_horizontal

Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 13, 2023

Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sul more_horizontal

Neuronetics to Present at the JMP Securities Life Sciences Conference

By GlobeNewsWire
May 9, 2023

Neuronetics to Present at the JMP Securities Life Sciences Conference

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical techn more_horizontal

Cannell Capital Now Owns 11.03% of Neuronetics

By 24/7 Wall Street
March 23, 2023

Cannell Capital Now Owns 11.03% of Neuronetics

Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM). more_horizontal

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 7, 2023

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hol more_horizontal

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

By GlobeNewsWire
February 22, 2023

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, more_horizontal

Why I Am Passing On BrainsWay And Neuronetics

By Seeking Alpha
February 17, 2023

Why I Am Passing On BrainsWay And Neuronetics

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, h more_horizontal


Search within

Pages Search Results: